Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Muggia

Showing results (361-370 of 424) with videos related to

Pageof 43
Sort By:
Investigational New Drugs|February 1, 1991
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group studyJ A Kish, K Kopecky, M K Samson, et al.
Cancer Treatment Reports|January 1, 1980
Phase II trials: use of a clinical tumor panel and overview of current resources and studiesF M Muggia, M Rozencweig, D F Chiuten, et al.
Cancer Research|December 1, 1993
Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease responseF A Blommaert, C Michael, P M Terheggen, et al.
Archives of Gynecology and Obstetrics|March 25, 2020
Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based studyKoji Matsuo, Rachel S Mandelbaum, Hiroko Machida, et al.
Investigational New Drugs|January 1, 1994
Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical toleranceF M Muggia, A Tulpule, A Retzios, et al.
Gynecologic Oncology|December 7, 2002
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary studyDebra Hawes, P Y Liu, Franco M Muggia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell linesYi-He Ling, Leonard Liebes, Jian-Dong Jiang, et al.
Cancer|February 1, 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancerL B Saltz, C G Leichman, C W Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
Cancer Research|August 15, 1993
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignanciesE Reed, R J Parker, I Gill, et al.
Pageof 43

Showing results (361-370 of 424) with videos related to

Sort By:
Pageof 43
Investigational New Drugs|February 1, 1991
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group studyJ A Kish, K Kopecky, M K Samson, et al.
Cancer Treatment Reports|January 1, 1980
Phase II trials: use of a clinical tumor panel and overview of current resources and studiesF M Muggia, M Rozencweig, D F Chiuten, et al.
Cancer Research|December 1, 1993
Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease responseF A Blommaert, C Michael, P M Terheggen, et al.
Archives of Gynecology and Obstetrics|March 25, 2020
Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based studyKoji Matsuo, Rachel S Mandelbaum, Hiroko Machida, et al.
Investigational New Drugs|January 1, 1994
Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical toleranceF M Muggia, A Tulpule, A Retzios, et al.
Gynecologic Oncology|December 7, 2002
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary studyDebra Hawes, P Y Liu, Franco M Muggia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell linesYi-He Ling, Leonard Liebes, Jian-Dong Jiang, et al.
Cancer|February 1, 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancerL B Saltz, C G Leichman, C W Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
Cancer Research|August 15, 1993
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignanciesE Reed, R J Parker, I Gill, et al.
Pageof 43